Joan N. Kyula

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling.

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling.

Journal: Journal for immunotherapy of cancer
Published: February 07, 2026

Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling.

Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling.

Journal: Journal for immunotherapy of cancer
Published: July 13, 2024

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy.

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy.

Journal: Nature communications
Published: January 05, 2024

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.

Journal: Journal for immunotherapy of cancer
Published: March 04, 2022

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.

Journal: Journal for immunotherapy of cancer
Published: February 06, 2022

Combination therapy with oncolytic viruses and immune checkpoint inhibitors.

Combination therapy with oncolytic viruses and immune checkpoint inhibitors.

Journal: Expert opinion on biological therapy
Published: February 19, 2020

The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism.

The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism.

Journal: Molecular therapy oncolytics
Published: June 25, 2019

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.

Journal: Journal for immunotherapy of cancer
Published: February 06, 2019

Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status.

Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status.

Journal: Frontiers in oncology
Published: December 01, 2017

Synergistic antitumour effects of rapamycin and oncolytic reovirus.

Synergistic antitumour effects of rapamycin and oncolytic reovirus.

Journal: Cancer gene therapy
Published: August 02, 2017

Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.

Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.

Journal: Science translational medicine
Published: September 03, 2016

HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.

HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.

Journal: BMC cancer
Published: August 03, 2016
Showing 1-12 of 27

Last Updated: 09/26/2026